Our preclinical study with Walter Reed Army Institute of Research (WRAIR) shows promising results for treating penetrating traumatic brain injury (TBI). This study evaluated the safety and efficacy of our hemostatic gel technology in treating TBI. Why does this matter? Penetrating TBI (such as from a gunshot or shrapnel) is the most severe form of traumatic head injury and can lead to death, permanent disability, neurodegenerative diseases, and long-term health issues. Since the DOD began tracking and reporting the number of service members diagnosed with TBI, a total of 492,167 service members sustained one or more TBIs, 5,766 of which were classified as penetrating TBI. "TBIs significantly impact the health, preparedness, and resilience of military personnel," said Dr. Anke Scultetus, WRAIR. "The results of this study with Cresilon are encouraging as we work to deliver solutions for medical personnel and our injured service members." Learn more at https://lnkd.in/e6zG4jN8 #TraumaticBrainInjury #HealthcareInnovation #EmergencyMedicine #TRAUMAGEL
About us
Headquartered in Brooklyn, New York, Cresilon, Inc. is a privately-held medical device company focused on hemostatic technologies that improve wound care and advance the standard of medical treatments. For more information, visit Cresilon.com. We are always looking for dynamic people to join our team as we dive into a range of challenges at the forefront of science and technology—to learn more about our openings please visit https://cresilon.workable.com/.
- Website
-
http://cresilon.com
External link for Cresilon
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Brooklyn, New York
- Type
- Privately Held
- Founded
- 2010
Locations
-
Primary
122 18th St
Brooklyn, New York 11215, US
Employees at Cresilon
-
Karina Duffy (Costantino)
-
Moshe Neuman
Angel investor from 0-10 Creative Connector and Community Builder | Visionary & Experienced Investor/Advisor & Mentor to 100+ Startups
-
John Luttati
Global Commercial Leader for Medical Device Companies
-
Karthik E.
Vice President, Operations & Supply Chain
Updates
-
Meet us at booth 23 at First There First Care & Gathering Of Eagles and learn about TRAUMAGEL's hemostatic capabilities. #biotech #ems #emergencymedicine
-
We're excited to announce a partnership with VerticalVet, bringing VETIGEL®, our hemostatic gel that stops bleeding in seconds, to over 1,800 veterinary clinics across the US. "VETIGEL's innovative products will significantly enhance our veterinarians' ability to manage bleeding in various clinical scenarios, improving patient outcomes and efficiency,” said Megan Sturgill, LVT, CVBL, Vice President of Operations with VerticalVet. This collaboration aligns perfectly with our mission to save lives, allowing us to reach more veterinarians across the USA. Learn more at https://lnkd.in/etfFiF7K #animalhealth #veterinarians #biotechnology
-
Cresilon reposted this
Listen to the GROW EVERYTHING podcast n.73: At The Bleeding Edge, where Karl Schmieder, MS MFA, Erum Azeez Khan, and Joe Landolina, CEO and Co-Founder of Cresilon, discuss everything from the untapped potential of animal health markets to the development of Cresilon's hemostatic technology. It's a must-listen for anyone interested in where biotech is headed next. Available on Apple, Google, and Spotify. Listen now: https://lnkd.in/emqvhr4r
-
Cresilon was recently recognized on Fast Company's annual list of the World's Most Innovative Companies, ranking number one in the medical devices category. We had an opportunity to sit down with Fast Company's editors to share more about the journey of advancing our life-saving technology. "Cresilon’s sophisticated products are remarkable for the science behind their development and their potential impact on lives worldwide. It’s that mix of high-tech research and broad-based application that has earned Cresilon a spot on Fast Company’s list of the World’s Most Innovative Companies in 2024." We continue advancing our mission of saving lives and thank our customers, partners, and team members for supporting this mission. #biotechnology #innovation #lifesciences For informational purposes only. TRAUMAGEL is currently not authorized for sale in the United States. For market authorization status of each product, visit FDA.gov
-
Honoring National EMS Week by expressing deep gratitude and respect for the outstanding work of EMS professionals. #nationalemsweek #emsweek
-
Listen to the GROW EVERYTHING podcast n.73: At The Bleeding Edge, where Karl Schmieder, MS MFA, Erum Azeez Khan, and Joe Landolina, CEO and Co-Founder of Cresilon, discuss everything from the untapped potential of animal health markets to the development of Cresilon's hemostatic technology. It's a must-listen for anyone interested in where biotech is headed next. Available on Apple, Google, and Spotify. Listen now: https://lnkd.in/emqvhr4r
-
We're thrilled to announce that Cresilon's hemostatic gel, VETIGEL®, is now available to veterinarians in the U.K. and across Europe through our partners at Veterinary Instrumentation (Vi), part of Covetrus. Since its launch in 2021, VETIGEL® has become the fastest and most effective hemostatic gel for veterinarians, used in over 50,000 procedures, including dental extractions, liver biopsies, mass removals, cleft palate repairs, amputations, and more. #animalhealth #biotechnology #veterinarymedicine
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus - Cresilon
http://cresilon.com
-
We’re attending SOMA 2024! Stop by booth 308 and learn how TRAUMAGEL® can advance the control of traumatic bleeding. __ #traumacare #biotech #soma2024